MedTrace Logo

Levosimendan In Patients Undergoing LVAD Implantation

NCT03659851 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-04-03

No results posted yet for this study

Summary

According to the results from the literature, it has been shown that levosimendan usage 24-48 hours before LVAD implementation can improve short and long-term outcome in these patients regarding to the patients without preoperative pretreatment. The aim is to compare short and long-term outcome in patients who underwent to LVAD implementation and pretreated with levosimendan regarding the patient without pretreatment or with other medications.

Conditions

  • Left Ventricular Dysfunction
  • Right Ventricular Dysfunction
  • Biventricular Failure

Interventions

DRUG

Levosimendan 2.5 MG/ML Injectable Solution

LVAD implantation

Sponsors & Collaborators

  • University Hospital Dubrava

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659851 on ClinicalTrials.gov